Instrument Inactif

Communiqués Oncobiologics Inc Nasdaq

Actions

US68235M2044

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

28/05	Outlook Therapeutics obtient l'autorisation de mise sur le marché de l'UE pour Lytenava dans le traitement de la DMLA humide	MT
28/05	Outlook Therapeutics, Inc. reçoit l'autorisation de mise sur le marché de la Commission européenne pour LYTENAVA ? (bvacizumab grapa) pour le traitement de la DMLA humide	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Outlook Therapeutics to Present at the Virtual Investor Pitch Conference	12/06	AQ
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference	11/06	AQ
European Biosimilar Regulatory Update	10/06	AQ
Corporate Presentation: June 2024	05/06	PU
Outlook Therapeutics Receives European Commission Marketing Authorization for LYTENAVA for the Treatment of Wet AMD	29/05	AQ
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD	28/05	AQ
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update	15/05	AQ
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD	13/05	AQ
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast	09/05	AQ
Outlook Therapeutics® to Present at the Retina World Congress 2024	02/05	AQ
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase	29/04	AQ
Outlook Therapeutics Announces Closing of Private Placement of $5.0 Million	16/04	AQ
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million	15/04	AQ
Corporate Presentation: March 2024	28/03	PU
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	25/03	AQ
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	22/03	AQ
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million	18/03	AQ
Outlook Therapeutics Announces Effective Date for 1-for-20 Reverse Stock Split	13/03	AQ
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split	12/03	AQ
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update	15/02	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Oncobiologics Inc Nasdaq

Actions

US68235M2044

Communiqués

Filtres